Table 2 Baseline characteristics of the total cohort and cases with or without IDC-P
| Â | Â | All patients (N=123) | Without IDC-P (N=46) | With IDC-P (N=77) | P value |
|---|---|---|---|---|---|
HRD score (median [IQR]) | Â | 21.0 [11.0, 28.5] | 14.0 [6.2, 24.8] | 23.0 [14.0, 30.0] | 0.002 |
 HRD score (%) | <21 | 58 (47.15) | 28 (60.87) | 30 (38.96) | 0.019 |
≥21 | 65 (52.85) | 18 (39.13) | 47 (61.04) |  | |
 Metastasis (%) | No | 45 (36.59) | 18 (39.13) | 27 (35.06) | 0.795 |
Yes | 78 (63.41) | 28 (60.87) | 50 (64.94) | Â | |
 Visceral metastasis (%) | No | 119 (96.75) | 44 (95.65) | 75 (97.40) | 0.997 |
Yes | 4 (3.25) | 2 (4.35) | 2 (2.60) | Â | |
 IDCP pattern (%) | 0 | 46 (37.40) | 46 (100.00) | 0 (0.00) | <0.001 |
1 | 19 (15.45) | 0 (0.00) | 19 (24.68) | Â | |
2 | 58 (47.15) | 0 (0.00) | 58 (75.32) | Â | |
 ISUP/WHO (%) | 1-3 | 20 (16.26) | 10 (21.74) | 10 (12.99) | 0.308 |
4-5 | 103 (83.74) | 36 (78.26) | 67 (87.01) | Â | |
Age (median [IQR]) | Â | 69.0 [64.0, 73.5] | 69.5 [67.0, 75.0] | 68.0 [62.0, 73.0] | 0.235 |
 Age (%) | <70 | 67 (54.47) | 23 (50.00) | 44 (57.14) | 0.56 |
≥70 | 56 (45.53) | 23 (50.00) | 33 (42.86) |  | |
PSA (median [IQR]) | Â | 67.8 [19.6, 100.1] | 75.1 [28.7, 100.1] | 60.0 [15.3, 100.1] | 0.187 |
 Baseline PSA (ng/mL, %) | <100 | 72 (58.54) | 26 (56.52) | 46 (59.74) | 0.872 |
≥100 | 51 (41.46) | 20 (43.48) | 31 (40.26) |  |